2018 SBIR and STTR Omnibus/Parent Grant Solicitations for the NIH, CDC, and FDA, Clinical Trial Not Allowed and Clinical Trial Required
New developments in traumatic brain injury prevention, diagnosis and treatment are certain to improve patient health among Soldiers, as well as improve Army readiness, said Tracie Lattimore, director of the Army’s Traumatic Brain Injury program within the Office of the Army Surgeon General.
Thinking you want to make a move to an innovative new tech hub that’s on the front line when it comes to education, research and business development? Forget the expected enclaves of cool like San Francisco or Brooklyn. In-the-know millennials have already moved on to the next innovation hubs.
Six months after closing its most recent funding, Protenus reported raising $11 million in Series B funding, and is planning more hiring.
NIH has launched a new series of initiatives to enhance the accountability and transparency of clinical research. ALL applications, including SBIR/STTR, proposing any specific aims that meet NIH’s definition of a clinical trial must now be submitted to a Funding Opportunity Announcement (FOA) that specifically states it accepts clinical trials. These initiatives target key points along the whole clinical trial lifecycle.
Virginia’s able new leaders have pledged bipartisan collaboration. Crafting a new investment strategy for the commonwealth would be an excellent place to start.
The technology industry will be a big part of Frederick County’s economic future, and the county has the young workers available to support the growth, the head of Frederick County’s Office of Economic Development believes.
Over the past few years, biotech startups have been successful at raising large amounts of capital just as they’re starting out. It has led to a lot of unicorns, with multibillion-dollar-valued companies having raised hundreds of millions in their series A or B rounds.
Montgomery County has been named one of 20 potential sites for Amazon’s second headquarters, the tech company announced Thursday morning.
Qiagen said today that the US Food and Drug Administration has extended the indications for use of its Therascreen EGFR RGQ PCR kit to guide the use of Boehringer Ingelheim’s Gilotrif (afatanib) for first-line treatment of patients with metastatic non-small cell lung cancer harboring non-resistant EGFR mutations.
